Skip to main content

Table 3 Late toxicities in patients treated with cetuximab + CCRT versus CCRT

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Late toxicity Cetuximab + CCRT
(n = 62)
CCRT
(n = 124)
P
Xerostomia* 11 (17.7%) 27 (21.8%) 0.52
Hearing loss* 13 (21.0%) 23 (18.5%) 0.694
Skin dystrophy 3 (4.8%) 5 (4.0%) 1
Neck fibrosis 6 (9.7%) 17 (13.7%) 0.431
Trismus 2 (3.2%) 11 (8.9%) 0.263
Radiation encephalopathy 1 (1.6%) 9 (7.3%) 0.108
Cranial nerve palsy 7 (11.3%) 9 (7.3%) 0.364
*Grade 2–4 toxicities    
  1. *grade 2-4 toxicities